Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 4(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03217578Recruiting

Neonatal Spinal Muscular Atrophy (SMA) Screening

Role: collaborator

NCT01522625Phase 4Completed

Tenofovir in Chronic Hepatitis B With Mild ALT Elevation

Role: collaborator

NCT02463019Phase 4Unknown

Roll-over After 3-year Trial for Tenofovir in Mild Chronic Hepatitis B

Role: collaborator

NCT01872988Phase 3Terminated

Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

Role: collaborator

NCT02075528Phase 4Completed

Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER

Role: collaborator

All 5 trials loaded